- Home
- NAKA vs PROK Comparison
NAKA vs PROK Comparison
Compare NAKA & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAKA
- PROK
- Stock Information
- Founded
- NAKA 2019
- PROK 2015
- Country
- NAKA United States
- PROK United States
- Employees
- NAKA N/A
- PROK N/A
- Industry
- NAKA
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NAKA
- PROK Health Care
- Exchange
- NAKA Nasdaq
- PROK Nasdaq
- Market Cap
- NAKA 126.6M
- PROK 85.5M
- IPO Year
- NAKA 2024
- PROK N/A
- Fundamental
- Price
- NAKA $7.98
- PROK $2.69
- Analyst Decision
- NAKA
- PROK Buy
- Analyst Count
- NAKA 0
- PROK 5
- Target Price
- NAKA N/A
- PROK $6.25
- AVG Volume (30 Days)
- NAKA 297.7K
- PROK 37.4M
- Earning Date
- NAKA 08-13-2025
- PROK 08-12-2025
- Dividend Yield
- NAKA N/A
- PROK N/A
- EPS Growth
- NAKA N/A
- PROK N/A
- EPS
- NAKA N/A
- PROK N/A
- Revenue
- NAKA $2,470,466.00
- PROK $306,000.00
- Revenue This Year
- NAKA N/A
- PROK $105.79
- Revenue Next Year
- NAKA N/A
- PROK N/A
- P/E Ratio
- NAKA N/A
- PROK N/A
- Revenue Growth
- NAKA N/A
- PROK N/A
- 52 Week Low
- NAKA $0.65
- PROK $0.46
- 52 Week High
- NAKA $34.77
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- NAKA N/A
- PROK 51.27
- Support Level
- NAKA N/A
- PROK $2.80
- Resistance Level
- NAKA N/A
- PROK $3.50
- Average True Range (ATR)
- NAKA 0.00
- PROK 0.58
- MACD
- NAKA 0.00
- PROK -0.16
- Stochastic Oscillator
- NAKA 0.00
- PROK 2.82
About NAKA Kindly MD Inc. Common Stock
Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.